Table 3.
Anti-adenovirus and neutralizing antibodies titer before (pre) and after (post) Ad-ISF35 injection
| Anti-adenovirus antibodies (EC50 dil−1) |
Anti-adenovirus neutralizing antibodies (EC50 dil−1) |
||||
|---|---|---|---|---|---|
| Cohort | Patient ID | Pre | Posta | Pre | Posta |
| 1 (1 × 1010 vp) | 1 | 244 ± 51 | 664 ± 87 | <50 | 60 |
| 2 | 635 ± 157 | 458 ± 89 | ND | ND | |
| 3 | 352 ± 60 | 317 ± 52 | ND | ND | |
| 2 (3.3 × 1010 vp) | 4 | 1,060 ± 94 | 1,619 ± 138 | 289 | 281 |
| 5 | 32 ± 16 | 30 ± 23 | ND | ND | |
| 6 | 944 ±145 | 622 ±104 | ND | ND | |
| 3 (1 × 1011 vp) | 7 | 891 ± 95 | 1,282 ±152 | <50 | <50 |
| 8 | 113 ± 29 | 186 ± 43 | ND | ND | |
| 9 | 470 ±114 | 475 ± 158 | ND | ND | |
| 4 (3.3 × 1011 vp) | 10 | 384 ± 80 | 1,888 ± 273 | 50 | 170 |
| 11 | 179 ± 46 | 3,571 ± 460 | <50 | 60 | |
| 12 | 178 ± 34 | 243 ± 51 | ND | ND | |
| 3E (1 × 1010 vp) | 13 | 21 ± 88 | 21 ± 88 | ND | ND |
| 14 | 173 ± 34 | 776 ±123 | <50 | <50 | |
| 15 | 837 ±160 | 752 ±123 | ND | ND | |
NOTE: Neutralizing antibodies assay was only conducted in samples showing increased titer after Ad-ISF35 IDI.
Abbreviation: ND, not determined.
a
Posttreatment evaluation conducted 1 month after Ad-ISF35 injection.